Consider the Bisphosphonate Dose

Affiliations

Free article

Editorial

Susan M Ott. J Bone Miner Res. 2022 Jan.

Free article

. 2022 Jan;37(1):1-2.

doi: 10.1002/jbmr.4479. Epub 2021 Dec 14.

No abstract available

Comment on

Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial.
Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Grey A, et al. J Bone Miner Res. 2022 Jan;37(1):3-11. doi: 10.1002/jbmr.4453. Epub 2021 Oct 13. J Bone Miner Res. 2022. PMID: 34585780 Clinical Trial.

1. Parfitt A. High bone turnover is intrinsically harmful: two paths to a similar conclusion. J Bone Miner Res. 2002;17:1558-1559.
1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
1. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322(12):802-809.
1. Chesnut C, McClung M, Ensrud K, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
1. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333(22):1437-1443.